Pegcetacoplan for treating C3 glomerulopathy or immune-complex membranoproliferative glomerulonephritis

Pegcetacoplan is in clinical development for treating C3 glomerulopathy (C3G) and primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN). C3G and primary IC-MPGN are both subtypes of membranoproliferative glomerulonephritis (MPGN). They result from an immune system disorder that causes antibodies and a substance called complement (C3) to be deposited in the kidneys, with evidence of immune complex deposition in the case of primary IC-MPGN, leading to inflammation that contributes to progressive renal injury. There is to date no specific treatment of C3G and primary IC-MPGN which directly targets C3 complement protein - the initial driver of the disease and possibly immunoglobulins deposition. There is a need for targeted therapies to improve the prognosis of both conditions.